Get started
EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals, Inc.EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

EYPT trade ideas

EYPT EyePoint Pharmaceutics LONGEYPT is now on another breakout on the 2h chart similar to what occurred from mid-December to mid-January. On the indicators the MACD shows the K/D lines on a steep upward slope. For me, what set off my interest was a relative volume scan that produced this stock on the list. The relative volume this week and consequential accumulation triggered the breakout with those volume spikes Fundamentally, EYPT had a catalyst as it completed one phase of its FDA clinical trials for a treatment for macular degeneration, a debilitating eye disease of the elderly. The potential market is several multiples of the stock's current market cap. This company is a takeover candidate as it is young without a big pipeline but with upside potential. The relative volume of 4X to 8X is a sure sign that buying pressure will move the price. Price has crossed the SMA50 just as it did last winter. The price is up 40% or more this week. Could this be a pump and dump? Maybe. For sure it is a speculation play just like many NASDAQ penny biotech stocks For mem the price action of last winter with a 120% gain in one month is reassurance for this time around with some hopeium thrown into the mix with the technical analysis. I will buy a call option under the current price with the 4/21 expiration and leverage the speculation a bit. In the past day, this option rose 67% based on the price surge of the underlying stock.
NASDAQ:EYPTLong
by AwesomeAvani
3
EYPT | Short term bottom? | LONGEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
NASDAQ:EYPTLong
by DivergenceSeeker
EYPT Breakout Stock Alert UpdateBREAKOUT STOCK ALERT UPDATE $EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock Status Alert: Deficient Initial Alert Price: $4.78 Price High: $6.23 % Gains/Losses: 30.33% (+19.33% More Than Expected) Potential Stop Loss: $5.92 EYPT hit $6.17 after retesting the $5.29 Levels as we predicted hitting its 52-Wk High. The stock looks like it may be falling back into consolidation after the breakout, but we're keeping this alert active until we can confirm a sell required to protect profits. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today Follow for more trade alerts and information & egister your account for Instant Alerts by clicking the link in our signature.
NASDAQ:EYPTLong
by MyMIWallet
Wedge setup: Pre-R/S #VolatilityWatchI’m sharing this as an impromptu for this upcoming weeks Earnings regarding what stock looks like pre-R/S, being this severely damaged. I look forward to seeing how management goes forward with addressing the company’s current financial state. Technicals : - Stock at bottom of wedge = Bullish, for bounce play, especially “good” on news. - Weekly RSI “oversold” - Trend lines converge into end of November. If we don’t get all news next week, likely test local ceiling/ floor by EOM. Why? : After several offerings and uncertainty due to loan covenant EYPT had made with CRG, Eyepoints stock price has been devastated. (Don’t forget covid). EYPT has upcoming Earnings on November 4th and had previously promised data on anti-vegf treatment “EYPT 1901” by October, 2020. With November and election days away, it is my belief that EYPT management/ BOD are waiting till next week to give news in hopes of catching good news pump from The company update in hopes they can serve Investors a side dish of R/S (Reverse split) to help EYPT meet listing requirements and to set themselves up for their next offering they’ll need - unless the company had some miracle blowout quarter., that is.. Furthermore, with rates as low as they are and as mad as it may sound, we may see them leverage the current low rates to keep cash afloat, as borrowing is currently very cheap. Again, I’m sharing this as an impromptu for this upcoming weeks’ Earnings and * hopeful * news regarding what stock looks like pre-R/S, being this severely damaged, and with supposed upcoming FDA filings. I look forward to seeing how management goes forward with addressing the company’s current financial state and using this data to help future financial decisions. Disclaimer: I am not a financial advisor. This is not a buy/ or sell recommendation it is to be used for educational purposes only.
NASDAQ:EYPTLong
by follow_the_money
$9.5 Million in Upfront Cash from Ocumension TherapeuticsEyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets. Ocumension has made a one-time $9.5 million payment to EyePoint for rights to commercialize both products under their own brand names in South Korea and other jurisdictions across Southeast Asia and as the full and final prepayment of all remaining development, regulatory, and commercial sale milestone payments under the original license agreements. finance.yahoo.com
NASDAQ:EYPT
by AlenCiken
Symmetrical Triangle BreakoutEYPT chart is building up for another run. Potential catalyst before year end with an sNDA for Short Duration Yutiq. accumulation has been slow and steady indicating EYPT oversold conditions. Technical's: weekly chart --> Harmonic Gartley (bounced off significant support level) and been in uptrend since. Symmetrical Triangle/ Breakout setup has been known to act as a pre-courser to huge upside moves (40%+). Bull flag building in the symmetrical triangle. . . Read the rest then check out the rest of our trade ideas HERE Disclosure: I am long EYPT. I am not a financial advisor and this is not a buy/ sell recommendation but for education purposes only. Please do your homework before investing.
NASDAQ:EYPTLong
by follow_the_money
$EYPT - Perfect Trend Retracement - Bulls Winning EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA. SHORT INTEREST 5.18M 09/30/19 P/E Current -1.93 P/E Ratio (with extraordinary items) -2.86 Average Recommendation: BUY Average Target Price: 5.13
NASDAQ:EYPTLong
by DEXWireNews
EYPT | Range bound Long-Term pattern suggests that after previous dilution, Eyepoint's stock price went range bound for quite awhile before breaking out. This marks potential accumulation range for anyone looking to build a position in EYPT. Ranges make for good swing trade positions (especially 20%+ both ways) and a way to average down. Range low/ highs, range from $1.42 - $1.87 is approximately $0.45 of profit both ways up (~20%+) until EYPT confirms they are adhering to terms of loan with CRG. Weekly MACD and Stochastics have divergence with stock price. This could infer spring board type action on good news (break below range could cause problems). Previous quarter showed that $EYPT was on track w/ meeting terms of CRG loan agreement. positive earning/ ER beat should help satisfy some hedge funds/ big $ investors. I remain cautiously optimistic. $EYPT could potentially come and test lows of the range within next week. I am looking to use this as a way to add to current position/ swing trade it to highs and lower cost basis on my long-position. **On the other hand, falling below this range could cause knee jerk reaction/ selloff. I am going to be watching this carefully. Tip # 7: When trading, It is very important to have a game plan. It is good practice to establish rules to your system (i.e. do you buy in increments?, at what point do you not like the investment anymore? how long are you willing to hold?). - Please Like and Follow for trade ideas & so I can continue to chart and build my reputation. Thank you in advance =) Have a Twitter? check out my page for more: @volatilitywatch Disclosure: I am long EYPT. This is not a note to buy or sell. Please do your homework before investing. //----------------------------------------------------------------------------------- Check out current trade in TGTX =) #BULLISH
NASDAQ:EYPTLong
by follow_the_money
EYPT on #VolatilityWatchEyepoint pharmaceuticals today was added to the Russell 2000 and 3000. The pharmaceutical company has alot to prove this quarter with regards to their loan with CRG, but a earnings beat would spark investor/ hedge fund investment which could give potential massive upside for EYPT and current investors. Why EYPT After EYPT diluted (one of EYPT's pain points) more share, EYPT ended up gaping down massively. Since then the company stock price has found itself range bound, making for a nice swing-trade for traders. Long-term resistance finally met with the range, the stock price was trading in. As of July 1, 2019 EYPT has broke out of the Long-Term resistance and looks to finally have more potential for upside. Other technicals that are appealing are: Extended inverse head and shoulders (bullish) - or - This could also be a potential Cup & Handle (reminder it just broke out of wedge). Elliott- Triangle - wave looks to be completed If EYPT fills gap, upside potential (and gap fill) would take SP to around $2.13. Disclosure: I am long EYPT. This is not a note to buy or sell. Please do your due diligence before investing.
NASDAQ:EYPTLong
by follow_the_money
EYPT showing resistance, with possible GAP fill!Based on the candle sticks presented, we can identify 2 key points that present opportunity in EYPT. First the “GAP” presented by the yellow highlight, when these gaps are formed and the stock starts to recover it is common for the price to rally back towards the price where the gap was created in this case roughly a bit under $2.20 ($2.11 was the lowest bid during the last 3 candles). Another identifiable point to notice is resistance at $1.74. During roughly the past 2 weeks the lowest the price rallied was $1.74 (3 times to be specific). Entry point is best when price surpasses $1.94, which was the highest bid since the GAP drop. It will demonstrate traders willing to push price further and recover the gap. If so the stock should be held till it roughly closes the gap, $2.11 is recommended to be the stop loss price, but depending on momentum, price could further rally to $2.20 or more. However, if price dips below $1.74, price could further be pushed down.
NASDAQ:EYPT
by AQube